C
Harmony Biosciences Holdings, Inc.
HRMY
$29.17
$0.180.62%
C
Hold
7/9/2024Upgraded
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C from C- on 7/9/2024 due to an increase in the volatility index.
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C from C- on 7/9/2024 due to an increase in the volatility index.
C
Hold
5/17/2024Downgrade
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to C- from C on 5/17/2024 due to a decline in the volatility index and valuation index.
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to C- from C on 5/17/2024 due to a decline in the volatility index and valuation index.
C
Hold
5/2/2024Upgraded
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C from C- on 5/2/2024 due to a noticeable increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.4468 to $0.67, EBIT increased 29.45% from $40.2M to $52.03M, and the quick ratio increased from 2.61 to 2.93.
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C from C- on 5/2/2024 due to a noticeable increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.4468 to $0.67, EBIT increased 29.45% from $40.2M to $52.03M, and the quick ratio increased from 2.61 to 2.93.
C
Hold
4/12/2024Downgrade
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to C- from C on 4/12/2024 due to a large decline in the growth index, valuation index and solvency index. EBIT declined 37.69% from $64.51M to $40.2M, the quick ratio declined from 3.9 to 2.61, and earnings per share declined from $0.63 to $0.4468.
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to C- from C on 4/12/2024 due to a large decline in the growth index, valuation index and solvency index. EBIT declined 37.69% from $64.51M to $40.2M, the quick ratio declined from 3.9 to 2.61, and earnings per share declined from $0.63 to $0.4468.
C
Hold
2/9/2024Upgraded
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C from C- on 2/9/2024 due to a noticeable increase in the volatility index.
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C from C- on 2/9/2024 due to a noticeable increase in the volatility index.
C
Hold
10/5/2023Downgrade
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to C- from C on 10/5/2023 due to a noticeable decline in the total return index, volatility index and solvency index.
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to C- from C on 10/5/2023 due to a noticeable decline in the total return index, volatility index and solvency index.
C
Hold
4/20/2023Downgrade
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to C from C+ on 4/20/2023 due to a significant decline in the total return index, growth index and volatility index. Operating cash flow declined 51.67% from $55.21M to $26.68M, and earnings per share declined from $1.44 to $0.7895.
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to C from C+ on 4/20/2023 due to a significant decline in the total return index, growth index and volatility index. Operating cash flow declined 51.67% from $55.21M to $26.68M, and earnings per share declined from $1.44 to $0.7895.
C
Hold
1/11/2023Downgrade
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to C+ from B- on 1/11/2023 due to a decline in the total return index.
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to C+ from B- on 1/11/2023 due to a decline in the total return index.
B
Buy
12/12/2022Upgraded
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to B- from C+ on 12/12/2022 due to an increase in the total return index and volatility index.
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to B- from C+ on 12/12/2022 due to an increase in the total return index and volatility index.
C
Hold
11/2/2022Upgraded
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C+ from C on 11/2/2022 due to a substantial increase in the valuation index, total return index and efficiency index. Net income increased 273.73% from $23.53M to $87.94M, and total capital increased 21.94% from $441.67M to $538.59M.
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C+ from C on 11/2/2022 due to a substantial increase in the valuation index, total return index and efficiency index. Net income increased 273.73% from $23.53M to $87.94M, and total capital increased 21.94% from $441.67M to $538.59M.
C
Hold
9/6/2022Downgrade
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to C from C+ on 9/6/2022 due to a large decline in the total return index.
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to C from C+ on 9/6/2022 due to a large decline in the total return index.
C
Hold
8/19/2022Upgraded
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C+ from C on 8/19/2022 due to a noticeable increase in the growth index, valuation index and total return index. Total revenue increased 25.45% from $85.31M to $107.03M, EBIT increased 20.18% from $27.56M to $33.12M, and operating cash flow increased 16.91% from $28.85M to $33.73M.
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C+ from C on 8/19/2022 due to a noticeable increase in the growth index, valuation index and total return index. Total revenue increased 25.45% from $85.31M to $107.03M, EBIT increased 20.18% from $27.56M to $33.12M, and operating cash flow increased 16.91% from $28.85M to $33.73M.
C
Hold
6/10/2022Upgraded
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C from C- on 6/10/2022 due to a noticeable increase in the total return index.
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C from C- on 6/10/2022 due to a noticeable increase in the total return index.
C
Hold
5/26/2022Downgrade
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to C- from C on 5/26/2022 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 23.13% from $37.53M to $28.85M, earnings per share declined from $0.3744 to $0.35, and total revenue declined 6.47% from $91.21M to $85.31M.
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to C- from C on 5/26/2022 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 23.13% from $37.53M to $28.85M, earnings per share declined from $0.3744 to $0.35, and total revenue declined 6.47% from $91.21M to $85.31M.
C
Hold
4/18/2022Upgraded
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C from C- on 4/18/2022 due to a major increase in the total return index, solvency index and volatility index.
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C from C- on 4/18/2022 due to a major increase in the total return index, solvency index and volatility index.
C
Hold
3/2/2022Upgraded
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C- from D on 3/2/2022 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from -$0.17 to $0.3744, EBIT increased 35.99% from $21.05M to $28.63M, and operating cash flow increased 23.37% from $30.42M to $37.53M.
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to C- from D on 3/2/2022 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from -$0.17 to $0.3744, EBIT increased 35.99% from $21.05M to $28.63M, and operating cash flow increased 23.37% from $30.42M to $37.53M.
D
Sell
11/10/2021Downgrade
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to D from D+ on 11/10/2021 due to a significant decline in the growth index, efficiency index and solvency index. Earnings per share declined from $0.24 to -$0.17, net income declined 168.14% from $14.12M to -$9.62M, and the quick ratio declined from 5.22 to 4.68.
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to D from D+ on 11/10/2021 due to a significant decline in the growth index, efficiency index and solvency index. Earnings per share declined from $0.24 to -$0.17, net income declined 168.14% from $14.12M to -$9.62M, and the quick ratio declined from 5.22 to 4.68.
D
Sell
10/1/2021Upgraded
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to D+ from D on 10/1/2021 due to a major increase in the growth index. Earnings per share increased from $0.1298 to $0.24, EBIT increased 60.41% from $14.53M to $23.31M, and operating cash flow increased 44.21% from $12.53M to $18.07M.
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to D+ from D on 10/1/2021 due to a major increase in the growth index. Earnings per share increased from $0.1298 to $0.24, EBIT increased 60.41% from $14.53M to $23.31M, and operating cash flow increased 44.21% from $12.53M to $18.07M.
D
Sell
3/4/2021Downgrade
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to D from D+ on 3/4/2021 due to a noticeable decline in the volatility index and total return index.
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to D from D+ on 3/4/2021 due to a noticeable decline in the volatility index and total return index.
D
Sell
11/19/2020Upgraded
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to D+ from D on 11/19/2020 due to a significant increase in the solvency index, efficiency index and total return index. Net income increased 7,170.37% from -$27 to $1.91M, total capital increased 95.37% from $147.11M to $287.41M, and the quick ratio increased from 4.35 to 7.49.
Harmony Biosciences Holdings, Inc. (HRMY) was upgraded to D+ from D on 11/19/2020 due to a significant increase in the solvency index, efficiency index and total return index. Net income increased 7,170.37% from -$27 to $1.91M, total capital increased 95.37% from $147.11M to $287.41M, and the quick ratio increased from 4.35 to 7.49.
D
Sell
11/12/2020None
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to D from U on 11/12/2020.
Harmony Biosciences Holdings, Inc. (HRMY) was downgraded to D from U on 11/12/2020.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
